Sinusitis News and Research

Latest Sinusitis News and Research

Ohio State, Nationwide Children's Hospital partner with ENTvantage for diagnosing bacterial sinusitis

The Ohio State University, through the Ohio State Innovation Foundation, and Nationwide Children's Hospital announced the signing of an exclusive, world-wide agreement with ENTvantage Diagnostics Inc. licensing a technology for rapid diagnosing of bacterial sinusitis.

22 Aug 2014

Research shows how bacteria in airways can help each other replenish vital iron

The body's assailants are cleverer than previously thought. New research from Lund University in Sweden shows for the first time how bacteria in the airways can help each other replenish vital iron.

5 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval.

9 Jun 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

New results from a randomized trial published in the American Journal of Rhinology and Allergy demonstrate the benefits of in-office balloon dilation for sufferers of chronic sinusitis.

15 May 2014

Pediatric viral respiratory tract infection often complicated by bacterial sinusitis

Nearly 1 in 10 cases of viral upper respiratory tract infections in infants and young children is complicated by acute bacterial sinusitis, often in conjunction with acute otitis media, a longitudinal cohort study has found.

22 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

FDA accepts AVP-825 NDA for acute treatment of migraine

The U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for AVP-825, an innovative closed-palate Breath Powered investigational drug-device combination product for the acute treatment of migraine.

27 Mar 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Taste receptors act as first line sentinels against infection in upper airway

The body uses mucus as a protective barrier to defend against pathogens, toxins, and allergens in the upper respiratory tract that can lead to such conditions as chronic sinusitis.

19 Feb 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Acclarent announces availability of Relieva Spin Balloon Sinuplasty System for sinusitis treatment

Acclarent, Inc. announced today the U.S. availability of the Relieva Spin Balloon Sinuplasty System with the M-110C Sinus Guide Catheter Tip designed to access small and tight sinus anatomy in children and adults. This innovation represents a new addition to Acclarent's Balloon Sinuplasty portfolio, which physicians use to treat children who suffer from chronic maxillary sinusitis.

23 Jan 2014

EMA expands administration options for Hizentra

CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®▼, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

5 Dec 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Sinusitis News and Research

Latest Sinusitis News and Research

Ohio State, Nationwide Children's Hospital partner with ENTvantage for diagnosing bacterial sinusitis

Research shows how bacteria in airways can help each other replenish vital iron

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

In-office treatment using balloon sinus dilation is as effective as FESS for chronic sinusitis

Pediatric viral respiratory tract infection often complicated by bacterial sinusitis

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

FDA accepts AVP-825 NDA for acute treatment of migraine

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Taste receptors act as first line sentinels against infection in upper airway

S. pneumoniae predicts acute sinusitis microbial response

Acclarent announces availability of Relieva Spin Balloon Sinuplasty System for sinusitis treatment

EMA expands administration options for Hizentra

Once-daily prescription medicine for COPD now available throughout the U.S.

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Sinusitis News and Research

Latest Sinusitis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in